Education
About Us
Working with TipRanks
Follow Us
NovoCure Ltd (NVCR)
NASDAQ:NVCR
NVCR Stock Chart & Stats
$12.06
-$0.69(-2.38%)
At close: 4:00 PM EST
$12.06
-$0.69(-2.38%)
Day’s Range― - ―
52-Week Range$10.70 - $34.13
Previous CloseN/A
Volume205.01K
Average Volume (3M)1.74M
Market Cap
$1.36B
Enterprise Value$1.21B
Total Cash (Recent Filing)$1.04B
Total Debt (Recent Filing)$797.94M
Price to Earnings (P/E)―
Beta1.47
Next Earnings
Feb 19, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding111,981,980
10 Day Avg. Volume1,757,783
30 Day Avg. Volume1,742,106
Financial Highlights & Ratios
PEG Ratio0.95
Price to Book (P/B)8.92
Price to Sales (P/S)5.31
P/FCF Ratio-46.42
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue1.88
Enterprise Value/Gross Profit2.49
Enterprise Value/Ebitda-11.24
Forecast
1Y Price Target
$27.00Price Target Upside123.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.4
Revenue Forecast (FY)$649.94M
Bulls Say, Bears Say
Bulls Say
Leadership And ManagementThe planned CEO transition with Frank Leonard as the new CEO is seen as a strategic move ahead of multiple new launches and international expansion for TTFields.
Market ExpansionOptune Lua national reimbursement in Japan for NSCLC is believed to support the slower-than-expected TTFields launch and enhance market presence.
Regulatory ApprovalsExpected FDA approvals for TTFields in locally advanced pancreatic cancer and brain metastases from NSCLC are anticipated to be key growth drivers.
Bears Say
Performance ConcernsThe launch of TTFields in NSCLC has trended slower than expected, which is a concern for the company's performance.
NovoCure News
NVCR FAQ
What was NovoCure Ltd’s price range in the past 12 months?
NovoCure Ltd lowest stock price was $10.70 and its highest was $34.13 in the past 12 months.
What is NovoCure Ltd’s market cap?
NovoCure Ltd’s market cap is $1.36B.
When is NovoCure Ltd’s upcoming earnings report date?
NovoCure Ltd’s upcoming earnings report date is Feb 19, 2026 which is in 70 days.
How were NovoCure Ltd’s earnings last quarter?
NovoCure Ltd released its earnings results on Oct 30, 2025. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.42 by $0.09.
Is NovoCure Ltd overvalued?
According to Wall Street analysts NovoCure Ltd’s price is currently Undervalued.
Does NovoCure Ltd pay dividends?
NovoCure Ltd does not currently pay dividends.
What is NovoCure Ltd’s EPS estimate?
NovoCure Ltd’s EPS estimate is -0.4.
How many shares outstanding does NovoCure Ltd have?
NovoCure Ltd has 111,981,980 shares outstanding.
What happened to NovoCure Ltd’s price movement after its last earnings report?
NovoCure Ltd reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.42. Following the earnings report the stock price went down -4.896%.
Which hedge fund is a major shareholder of NovoCure Ltd?
Currently, no hedge funds are holding shares in NVCR
NovoCure Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$27.00 (123.88% Upside)
$27.00 (123.88% Upside)
Blogger Sentiment
Bullish
NVCR Sentiment 83%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 760.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-56.86%
12-Months-Change
Fundamentals
Return on Equity
-50.60%
Trailing 12-Months
Asset Growth
11.39%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
NovoCure Ltd
NovoCure Limited is a commercial stage oncology company focused on the development and commercialization of its proprietary Tumor Treating Fields (TTFields) therapy. This innovative treatment modality uses electric fields to disrupt cancer cell division, offering a non-invasive option primarily for patients with glioblastoma and mesothelioma. NovoCure operates in the healthcare sector, specifically in oncology, and its core product is the Optune device, which delivers TTFields therapy to patients.
NVCR Company Deck
NVCR Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlights strong growth in the GBM segment and international markets, along with regulatory progress for new indications. However, these positives are tempered by challenges in the non-small cell lung cancer launch, flat growth in the U.S. market, and financial setbacks such as reduced gross margin and net loss.View all NVCR earnings summariesNVCR Net revenue Breakdown
68.67% U.S.
11.82% Germany
8.74% Japan
6.22% Other EMEA
4.56% Greater China
NVCR Stock 12 Month Forecast
Average Price Target
$27.00
▲(123.88% Upside)
Technical Analysis
Ownership Overview
2.19% Insiders
27.33% Mutual Funds
19.06% Other Institutional Investors
35.68% Public Companies and Individual Investors